Pharmacotherapy for atrial fibrillation in elderly hospitalized patients with comorbid congestive heart failure in australia: A retrospective study

Current Therapeutic Research - Clinical and Experimental

Volumn 69, Issue 6, 2008, Pages 514-524

  Wang, Lexin ^a   Curran, Shane ^b   Ball, Patrick ^a   White, Fiona ^a  

^a Charles Stmt University   (Australia)

^b Wagga Wagga Base Hospital   (Australia)

Author keywords

antiarrhythmic drugs; anticoagulation; atrial fibrillation; heart failure; rate control

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; SOTALOL; SPIRONOLACTONE; VERAPAMIL; WARFARIN;

AGED; AGING; ARTICLE; AUSTRALIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG USE; ELDERLY CARE; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 68749116800     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.12.001     Document Type: Article

References (31)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 316 (1987) 1429-1435
2. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 98 (1998) 946-952
3. Pederson O.D., Søndergaard P., Nielsen T., et al. for the DIAMOND Study Group Investigators. Atrial fibrillation, ischaemic heart disease, and the risk of death in patients with heart failure. Eur Heart J 27 (2006) 2866-2870
4. Gosselink A.T., Crijns H.J., Van Gelder I.C., et al. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 267 (1992) 3289-3293
5. Chun S.H., Sager P.T., Stevenson W.G., et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 76 (1995) 47-50
6. Olshansky B., Rosenfeld L.E., Warner A.L., et al., for the AFFIRM Investigators. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study: Approaches to control rate in aerial fibrillation. J Am Coll Cardiol 43 (2004) 1201-1208
7. Oake N., Fergusson D.A., Forster A.J., and van Walraven C. Frequency of adverse events in patients with poor anticoagulation: A meta-analysis. CMAJ. 176 (2007) 1589-1594 [published correction appears in CMAJ. 2007;177:271]
8. Sherman D.G., Kim S.G., Boop B.S., et al., for the National Heart, Lung, and Blood Institute AFFIRM Investigators. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) Study. Arch Intern Med 165 (2005) 1185-1191
9. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 84 (1991) 527-539
10. Miller V.T., Rothrock J.F., Pearce L.A., et al., for the Stroke Prevention in Atrial Fibrillation Investigators. Ischemic stroke in patients with atrial fibrillation: Effect of aspirin according to stroke mechanism. Neurology 43 (1993) 32-36
11. Petersen P., Boysen G., Godtfredsen J., et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study. Lancet 1 (1989) 175-179
12. Monte S., Macchia A., Pellegrini F., et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. Eur Heart J 27 (2006) 2217-2223
13. Evans A., Perez I., Yu G., and Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation?. Stroke. 32 (2001) 2828-2832
14. Jackson S.L., Peterson G.M., Vial J.H., et al. Outcomes in the management of atrial fibrillation: Clinical trial results can apply in practice. Intern Med J 31 (2001) 329-336
15. Nieuwlaat R., Capucci A., Camm A.J., et al., for the European Heart Survey Investigators. Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005) 2422-2454
16. Tapson V.F., Hyers T.M., Waldo A.L., et al. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. for the NABOR (National Anticoagulation Benchmark and Outcomes Repott) Steering Committee. Arch Intern Med. 165 (2005) 1458-1464
17. Cohen N., Almoznino-Sarafian D., Alon I., et al. Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission. Stroke. 31 (2000) 1217-1222
18. Jackson S.L., Bereznicki L.R., Peterson G.M., et al. Accufacy and clinical usefulness of the near-patient testing CoaguChek S international normalised ratio monitor in rural medical practice. Amt J Rural Health. 12 (2004) 137-142
19. World Health Organization International Classification of Diseases, Ninth Revision, Clinical Modification (2003), Centers for Disease Control Web site. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD9-CM/2003/ Accessed November 20, 2008
20. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 111 (2005) 697-716
21. Fuster V., Rydén L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published correction appears in Circulation. 2007;116:e138]. for the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, the European Society of Cardiology Committee for Practice Guidelines, the European Heart Rhythm Association, the Heart Rhythm Society. Circulation 114 (2006) e257-e354
22. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the firsr 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). for the ADHERE Scientific Advisory Committee and Investigators. Am Heart J. 149 (2005) 209-216
23. Nikolaidou T., and Channer K.S. Rate control in permanent atrial fibrillation. BMJ. 335 (2007) 1057-1058
24. Khand A.U., Rankin A.C., Martin W., et al. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?. J Am Coll Cardiol. 42 (2003) 1944-1951
25. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised rrials. Lancet. 350 (1997) 1417-1424
26. Smith N.L., Psaty B.M., Furberg C.D., et al. Tempofal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med. 159 (1999) 1574-1578
27. McGlynn E.A., Asch S.M., Adams J., et al. The quality of health care delivered to adults in the United States. N Engl J Med. 348 (2003) 2635-2645
28. Bungard T.J., Ghali W.A., Teo K.K., et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med. 160 (2000) 41-46
29. Peterson G.M., Boom K., Jackson S.L., and Vial J.H. Doctots' beliefs on the use of antithrombotic therapy in atrial fibrillation: Identifying barriers to stroke prevention. Intern Med J. 32 (2002) 15-23
30. Bradley B.C., Perdue K.S., Tisdel K.A., and Gilligan D.M. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol. 85 (2000) 568-572
31. Choudhry N.K., Soumerai S.B., Normand S.L., et al. Warfarin prescribing in atrial fibrillation: The impact of physician, patient, and hospital characteristics. Am J Med. 119 (2006) 607-615